Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

W. Roberts, Andrew; S. Davids, Matthew; M. Pagel, John; S. Kahl, Brad; D. Puvvada, Soham; F. Gerecitano, John; J. Kipps, Thomas; Ann Anderson, Mary; R. Brown, Jennifer; A. Gressick, Lori; Wong, Shekman; Dunbar, Martin; Zhu, Ming; Desai, Monali; Cerri, Elisa; H. Enschede, Sari; Humerickhouse, Rod; G. Wierda, William; F. Seymour, John

doi:10.1056/nejmoa1513257

Public

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Published in New England Journal of Medicine • Dec 6, 2015

Authors:

Andrew W. Roberts

Matthew S. Davids

John M. Pagel

Abstract

BACKGROUND: New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. METHODS: We conducted a phase 1 do...

Subject

Venetoclax

Medicine

Fludarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!